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Abstract
Background: Atopic dermatitis (AD) is associated with reduced skin microbial diversity and overgrowth of
Staphylococcus (S.) aureus. However, the importance of S. aureus colonisation in the complex pathogenesis remains
unclear and studies on the effect of anti-staphylococcal therapy in non-infected AD show contradictory results. Long-term
interventions against S. aureus might be needed to restore the microbial balance, but carry the risk of bacterial resistance
induction. Staphefekt, an engineered bacteriophage endolysin, specifically kills S. aureus leaving other skin commensals
unharmed. Bacterial resistance towards endolysins has not been reported, nor is it expected, which allows us to study its
effect as long-term anti-staphylococcal treatment in non-infected AD.
Methods: This is a multi-centre, placebo-controlled, double-blinded and randomized superiority trial with a parallel group
design. A total of 100 participants, aged 18 years or older, diagnosed with moderate to severe AD and using a topical
corticosteroid in the weeks before enrolment are included in the study. The study is executed in the Erasmus MC
University Medical Centre Rotterdam in collaboration with the Havenziekenhuis Rotterdam. After a 2-week run-in period
to standardize the corticosteroid use with triamcinolone acetonide 0.1% cream, participants will be randomized to either
treatment with Staphefekt in a cetomacrogol-based cream or a placebo for 12 weeks, followed by an 8-week follow-up
period. The primary objective is to assess the difference in the need for corticosteroid co-therapy between the Staphefekt
and the placebo group, measuring the number of days per week of corticosteroid cream (triamcinolone) use. Secondary
outcomes include the difference in use of corticosteroid cream measured in grams, differences in clinical efficacy, quality
of life (QoL), microbial composition (includi23ng S. aureus) between the Staphefekt and the placebo group, and the
safety and tolerability.
Discussion: The results of this trial will provide data about the effect of long-term anti-staphylococcal therapy with
Staphefekt on corticosteroid use, clinical symptoms and QoL in patients with moderate to severe AD. Additional data
about growth characteristics of the skin microbiome, including S. aureus, will give insight into the role of the
microbiome as a factor in the pathophysiology of AD.
Trial registration: ClinicalTrials.gov, NCT02840955. Registered on 11 July 2016.
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Background
Atopic dermatitis (AD) is a chronic inflammatory skin
disease that is associated with reduced quality of life
(QoL), primarily due to itchy skin [1–3]. The disease is
characterised by reduced skin microbial diversity and
overgrowth of Staphylococcus (S.) aureus, a bacterium
that can aggravate skin inflammation via the production
of staphylococcal enterotoxins that stimulate the release
of pro-inflammatory cytokines [4–7]. However, the im-
portance of S. aureus colonisation in the complex patho-
genesis, compared to the other genetic and immunologic
factors involved, remains unclear.
Current treatment approaches for AD include topical
treatment with emollients and anti-inflammatory therapy
with (topical) immunosuppressive agents (corticosteroids
and calcineurin inhibitors), according to the international
guidelines [8, 9]. Anti-staphylococcal therapy is only
recommended in cases of fever or clinically infected skin
[8, 9]. Clinical studies that evaluated the added value of
anti-staphylococcal therapy in non-infected AD, have
shown contradictory results. Bath Hextall et al. performed
a systematic review of 26 studies and showed that anti-
staphylococcal agents reduced the amount of S. aureus on
the skin in AD. However, the bacteriological reduction did
not translate into a decrease in clinical symptoms [10].
These studies mainly investigated short-term therapies of
less than one month duration and comprised small and
poor-quality studies. As discontinuation of therapy after a
short treatment period can result in quick regrowth of S.
aureus [11], the results of this systematic review do not
necessarily mean that anti-staphylococcal agents do not
work. A more recent review by Brüssow et al. summarizes
two intervention trials that reported significant reduction
in disease severity in non-infected AD after 2 and
3 months of therapy with anti-staphylococcal therapy
(bleach baths) [12–14]. We hypothesize that long-term
therapy may be needed to reduce S. aureus overgrowth
and maintain a stable and balanced skin microbial com-
position. Ultimately, this could result in disease improve-
ment, prevention of AD flares and less need for (topical)
immune suppression. However, long-term use of antibi-
otics can induce bacterial resistance [15], and both the use
of antibiotics and dilute bleach baths can cause unneces-
sary harm to the commensal flora, that is hypothesized to
have anti-staphylococcal properties [16].
In the context of the increasing incidence of bacterial
resistance, the interest in bacteriophages and their endo-
lysins as antibacterial therapy has been renewed [17].
Staphefekt SA.100 is an engineered chimeric endolysin
that specifically lyses the cell membrane of S. aureus via
endopeptidase and putative amidase activities [18–20].
Long-term application of Staphefekt on the skin, target-
ing only S. aureus and leaving skin commensals
unharmed, may improve long-term AD outcomes, such
as the number of disease flares, and may reduce the use of
topical corticosteroids. Bacterial resistance to Staphefekt
or other endolysins has not been observed and could not
be induced, which enables us to study the effect of long-
term anti-staphylococcal treatment in non-infected AD
using this endolysin-based agent [19, 21, 22].
The aim of this randomized controlled trial, the
MAAS trial, is to evaluate the effect of 3-month anti-
staphylococcal therapy with Staphefekt on the frequency
and quantity of topical corticosteroid use, clinical symp-
toms and QoL in patients with moderate to severe AD.
In addition, data on the growth characteristics of the
skin microbiome, including S. aureus, will be collected,
which will gain insight into the role of the microbiome
as a factor in the pathophysiology of AD.
Methods/design
Design and setting
The MAAS trial (Microbiome in atopic dermatitis during
anti-staphylococcal therapy and the effect on steroid use), is
a multi-centre, randomized, double-blinded, placebo-
controlled superiority trial with a parallel group design
(Fig. 1). The study aims to evaluate the effect of Staphefekt
on the use of corticosteroids, disease severity, QoL and
composition of the microbiome in patients with AD. The
study was designed by the Department of Dermatology of
the Erasmus MC University Medical Centre Rotterdam and
will be executed in collaboration with the Havenziekenhuis
Rotterdam. Enrolment and follow-up visits take place at
these two locations. Participants who comply with the cri-
teria for inclusion and exclusion will start with a 2-week
run-in period to standardize the corticosteroid use with
triamcinolone acetonide 0.1% cream. After completion of
the run-in phase, participants will be randomized to either
treatment with Staphefekt or a placebo for 12 weeks,
followed by an 8-week follow-up period. An Eczema Area
Severity Index (EASI) above 50 after the run-in phase is a
contraindication for further participation. During the
course of the study, participants visit the outpatient clinic
six times (visit 1 through 6) and data will be collected on
corticosteroid use, disease severity, QoL, skin microbiome
and adverse events. See Additional file 1 for an overview of
the Standard Protocol Items: Recommendations for Inter-
ventional Trials (SPIRIT) 2013 checklist items. See Table 2
for the SPIRIT diagram of the trial procedures.
Ethical considerations
This study follows the Dutch Medical Research Involving
Human Subjects Act 1998 (WMO) and the principles of
the Helsinki Declaration 2008. All study procedures have
been reviewed and approved by the Medical Ethics Com-
mittee of the Erasmus MC University Medical Centre
Rotterdam, The Netherlands (reference 2016-233). Protocol
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amendments will be submitted for review at the Medical
Ethics Committee.
Participants
This study will enrol adults (18 years or older) diagnosed
with AD according to the UK working party diagnostic
criteria for AD [23–25]. Participants are eligible for
enrolment if they have a score between 7.1 and 50.0 on
the EASI for disease severity. Topical corticosteroids
must have been prescribed before enrolment. All
patients must be able to read and understand the patient
information and provide written informed consent.
Patients are not eligible for enrolment if they used: (1)
systemic antibiotics or corticosteroids in the 2 months
prior to enrolment, (2) oral immunosuppressive agents or
UV therapy in the 3 months before enrolment or (3) local
antibiotics or Staphefekt (from commercial sources)
1 week before enrolment. Other criteria for exclusion are
known contact allergy to any of the components of the
study drug (e.g. propylene glycol), clinically infected AD
or the existence of other skin condition(s) that could
interfere with the assessment of the AD severity.
Recruitment, inclusion and consent
Participants with AD will be recruited from the
dermatology outpatient clinic of the Erasmus MC and
the Havenziekenhuis Rotterdam. Furthermore, Dutch
dermatologists are informed about the study via the Dutch
Trial Network and via scientific conferences. Patients with
AD are informed via the patient support group and via
online media, such as DermHome (https://www.huid-
huis.nl/). In addition, recruiting advertisements will be
placed on student forums and in local newspapers. Pa-
tients who are interested in participation in the trial can
contact the researcher directly via email or phone. After a
first screening with regard to the inclusion and exclusion
criteria via email or phone, potentially eligible participants
receive an information letter and will be invited to the
dermatology outpatient clinic to further assess eligibility.
Patients who fulfil the inclusion criteria and are willing to
participate, will be included in the study after providing
written informed consent.
Sample size
The sample size for this study was calculated based on the
primary outcome, namely the difference in mean days per
week of corticosteroid use over 12 weeks between the
Staphefekt arm and the placebo arm, in patients who are
positive for S. aureus on the skin at baseline. This is the
first study measuring clinical outcomes of Staphefekt in
patients with AD. We expect to find a mean topical
corticosteroid use of 5 days/week in the placebo group.
This was based on a study by Hon et al. that showed
decreased use of topical corticosteroids when taking
Fig. 1 Flowchart of the study design
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bleach baths, an anti-staphylococcal therapy [26]. Based
on the results of this study, we anticipate an effect size of
1.25 day/week reduction in topical corticosteroid use in
the Staphefekt arm. A sample size was calculated using
the unpaired t test to compare means in a superiority trial
design. With power of 0.80, alpha of 0.05 and SD of 2.0,
40 patients are needed per treatment arm. Assuming 10%
drop out and 90% of the patients being positive for S.
aureus on the skin lesions, 50 patients will be assigned to
each of the two treatment arms.
Randomization and blinding
The participants are randomly assigned, in a 1:1 fashion
to either treatment with Staphefekt or placebo. Stratified
block randomization for AD severity is performed to
ensure equal distribution of patients with moderate and
severe AD over the treatment arms (EASI 7.1–21 and
EASI 21.1–50). Randomization is done by an independ-
ent biostatistician of the Erasmus MC, using the statis-
tical software package R version 3.2.2. The participants,
the researchers and laboratory analyst are blinded to the
intervention. The pharmacy manages the randomization
list and provides blinded study medication.
Intervention
After enrolment, all participants start a run-in phase of
2 weeks in which they receive a standardized dosing
regimen of topically applied triamcinolone acetonide
0.1% cream (Table 1). After the run-in period, the pa-
tient and the researcher evaluate further participation,
with very severe AD (EASI >50) as a contraindication
for continuation. The run-in period and randomization
is followed by a 12-week treatment period and an 8-
week follow-up period. During the treatment period,
Staphefekt or placebo cream will be applied on the total
skin surface twice daily to reach optimal reduction of S.
aureus, as both lesional and non-lesional skin are often
colonised [4]. The Staphefekt endolysin is made available
in a cetomacrogol-based cream. The placebo is com-
posed of the same cetomacrogol-based cream, without
Staphefekt. During the treatment and follow-up period
triamcinolone will be used according to the corticosteroid
dosing regimen (Table 1). Measurements and assessments
will be performed at enrolment (start of the run-in phase,
visit 1), baseline (start treatment with Staphefekt/placebo,
visit 2a), 0.5 hours after baseline and 2, 6, 12 and 20 weeks
after baseline (visit 2b to 6). Table 2 provides an overview
of the measurements per visit. Unless it is in the best
interest of the patients (for example in the case of an
eczema flare), patients are not allowed to use systemic or
topical immunosuppressive medication (including calcine-
urin inhibitors), antibiotics or antiseptics during the study.
Escape medication will be prescribed according to current
treatment guidelines and its use will be registered. At the
start of the study, patients receive an emollient according
to the patient’s preference for use during the course of the
study. The use of this emollient will be registered by
weighing the tubes at each visit.
Detailed sample and laboratory procedures
Sampling procedures are based on the “Manual of
Procedures” for microbiome sampling of the Human
Microbiome Project [27]. All samples are obtained by
one of the researchers wearing gloves (sterile for the
skin scrub). Sterile Copan 490CE.A swabs are used to
sample the skin, nasal cavity and pharynx. Skin sam-
ples are taken from lesional skin, preferably located at
the antecubital folds or the popliteal fold. The skin
surface is swabbed for 30 seconds. The mucosal sur-
faces of both the anterior nares are gently rubbed,
going round the area for 10 seconds. The rear of the
oropharynx is swabbed for 5 seconds using a tongue
depressor. For the skin scrub sample, a ring with an
internal diameter of 4 cm will be placed on the same skin
lesion where the swab was collected, but on a non-
overlapping area: 1 ml of swab solution (0,85% NaCl, 0.1%
bacteriological peptone, 0.1% Tween 80) is pipetted into
the ring. After rubbing over the skin with a Copan 480CE
swab for 1 minute, the swab solution will be pipetted out
of the ring into an Eppendorf tube. The swabs will be sent
to the laboratory by mail on the day of collection. A semi-
quantitative culture technique and matrix-assisted laser
Table 1 Corticosteroid dosing regimen
Week 1 Week 2 Week 3 Week 4 Week 5 Week 6 Week 7 Week 8 Week 9
Saturday X X X X X
Sunday X X X X X X X
Monday X X X X X
Tuesday X X X X X
Wednesday X X X X X
Thursday X X X X X X X
Friday X X X X X
Start in week 1 or 2 depending on severity of the atopic dermatitis. If the symptoms allow, reduce the use of corticosteroid cream weekly according to the
scheme. Return to week 1 or 2 in the case of an exacerbation. Based on patient assessment
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Table 2 SPIRIT diagram of study procedures [28–32]
Visit 1, enrolment in the trial and start of a 2-week run-in phase; visit 2a, start of the intervention (baseline); visit 2b, 0.5 hours after baseline; visit 3, 2 weeks after baseline; visit 4, 6 weeks
after baseline; visit 5, 12 weeks after baseline and end of the intervention; visit 6, follow-up visit 20 weeks after baseline. All visits take place plus or minus 2 days from the indicated
timeframe. EASI Eczema Area and Severity Index, IGA Investigator’s Global Assessment, Pruritus NRS Pruritus Numerical Rating Scale, POEM Patient Orientated Eczema Measure
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desorption ionization time-of-flight (MALDI-TOFF) for
identification of S. aureus will be performed. The scrub
samples will be stored at –80 °C at the Erasmus MC
Rotterdam until 16S rRNA-sequencing and quantitative
S. aureus analysis.
Primary and secondary outcomes
The primary outcome of this study is the days per week of
corticosteroid use, compared between the Staphefekt and
the placebo group over 12 weeks. Patients report their
triamcinolone use daily in a secured digital platform,
“DermHome”.1 Additionally, the use of triamcinolone
cream will be measured in grams by weighing the study
medication at the time of issue and return (each visit).
Secondary outcomes include clinical efficacy and QoL
from baseline through week 12 and week 20, change in the
microbial composition (including S. aureus) and safety.
Clinical efficacy is measured using the EASI, the Investiga-
tor’s Global Assessment (IGA) and registration of the num-
ber of flares [28]. A flare is defined as an exacerbation that
requires the need to intensify treatment, from a doctor or
patient’s perspective. This implies stronger topical therapy
or the need for systemic treatment. A 50% increase in the
EASI score compared to baseline is used as an indication
to intensify treatment. The Pruritus Numerical Rating
Scale (Pruritus NRS) and the Patient Orientated Eczema
Measure (POEM) are included as patient-reported efficacy
outcomes [29, 30]. QoL is measured using the Skindex-29
[31, 32]. Changes in the microbiome are evaluated by
comparing the changes in bacterial composition between
the treatment groups, determined by 16S rRNA sequen-
cing of the skin scrub samples. Reduction in S. aureus is
determined by quantitative PCR (and culture for the
comparison between visit 2a and visit 2b). Safety and toler-
ability is assessed by monitoring the incidence of (serious)
adverse device events through the end of the study, evalu-
ated by medical check-ups that include evaluation of vital
signs. Reportable adverse events will be reported within
the set timelines to the competent authorities. Table 2 gives
a detailed overview of the measurements per visit.1
Data collection, monitoring and data analysis
Data collected during the visits are entered in Open
Clinica. This data management system allows direct data
entry. Data entry is monitored by an independent
researcher according to a predefined monitoring plan.
Triamcinolone use and itch scores filled in daily by the
patients in “DermHome” will be extracted in an SPSS
format and combined with the Open Clinica database.
Patient confidentiality will be ensured by using identifi-
cation numbers. Data will be analysed on an intention-
to-treat basis. A mixed linear regression model will be
used to examine if there is a significant difference in cor-
ticosteroid use over 12 weeks between the intervention
and the placebo group [34]. This model accounts for
repeated measurements in each patient and is valid in
the case of missing data. Covariates that could influence
the outcome variable will be included in the model. Sub-
group analysis will be performed to analyse patients who
are positive for S. aureus on the skin versus patients that
are negative for S. aureus before the start of the inter-
vention. Positive patients are defined as having positive
cultures both at visit 1 and 2a. Negative patients must
have two negative cultures. Patients that have one posi-
tive and one negative culture will not be included in the
subgroup analysis. Secondary outcomes will also be
analysed using a mixed model analysis (linear or logistic
according to the type of data). The findings of this study
will be published in national and international jour-
nals (according CONSORT 2010 Statement) and will
be communicated to the relevant patient associations.
Discussion
The MAAS trial is a randomized, placebo-controlled trial
that investigates the effect of 3-month anti-staphylococcal
therapy with Staphefekt on topical corticosteroid use, clin-
ical symptoms and QoL in adults with moderate to severe
AD. Additionally, data will be collected about the growth
characteristics of the skin microbiome, including S.
aureus. Taking into consideration the current literature on
anti-staphylococcal therapy, a study design using a long-
term anti-staphylococcal intervention, measuring long-
term outcomes was chosen.
Evidence for the clinical efficacy of Staphefekt, registered
as a class 1 medical device in Europe, is based on in vitro
studies and a case series [18–20]. These in vitro studies
showed that Staphefekt kills different strains of S. aureus
(also methicillin-resistant strains), without harming the
commensal flora or inducing bacterial resistance [19]. A
case series describes clinical improvement in S. aureus re-
lated symptoms, such as folliculitis and superinfected
dermatitis, and no development of resistance during long-
term daily treatment with Staphefekt based on the min-
imal inhibitory concentrations of the cultured S. aureus
strains over time [35]. The lack of resistance induction
can be expected, as bacterial killing by an endolysin is
independent of the involvement of the bacterial me-
tabolism. The co-evolution of bacteriophages and
their host bacteria over millions of years, ensures that
phage endolysins attack essential bonds in the bacter-
ial cell wall that cannot be adapted by the host [22].
Thereby, the lytic activity of exogenously applied
endolysins results in lysis of the target cells within
seconds, restricting the possibility to adapt and de-
velop resistance. Furthermore, attacking several bonds
of the bacterial wall simultaneously by the use of
more than one enzymatically active domain in the
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Staphefekt molecule, makes resistance even less likely
to develop [18].
Because of the proteinaceous nature of endolysins, im-
munogenicity can be of concern. The literature shows the
possibility of the formation of non-neutralizing antibodies
against lysins other than Staphefekt [22]. In a study in
which the presence of anti-Staphefekt IgG was evaluated in
serum from 21 Staphefekt-naive healthy human donors,
pre-existent IgG antibodies recognizing Staphefekt epitopes
were detected in all the donors (unpublished data). This
can be explained, as humans are exposed daily to S. aureus
and therefore to bacteriophages and their lysins. However,
Staphefekt is a large protein molecule (>50 kDa), making
penetration through the skin and mucosa and subsequent
antibody reactions unlikely [36].
Calculation of the sample size for this study was ham-
pered as no information was available about the effect of
Staphefekt on corticosteroid use and clinical efficacy in AD.
Therefore, the study should be considered as hypothesis
generating, giving insight into effect sizes and distributions
of clinical outcomes. Our expected effect size was based on
a study of Hon et al. of the effect of bleach on corticoster-
oid use in AD. We chose a slightly higher effect size, be-
cause we expect the effect of Staphefekt that specifically
targets S. aureus to be more efficacious than bleach. We
consider this effect size, a reduction in corticosteroid use of
more than 1 day a week over 12 weeks, as clinically relevant
because of the (low) risk of side effects and a general reluc-
tance of patients to use corticosteroids, resulting in poor
compliance and a lack of treatment efficacy [37, 38].
No consensus has been reached yet on a standardized
outcome for long-term AD control, the primary goal of
our study. The Harmonising Outcome Measures for
Eczema (HOME) initiative reached consensus on the use
of EASI and POEM as doctor-based and patient-based
measures of AD severity, both of which are included as
secondary outcomes in this trial [39]. According to the
authors of HOME, measures of long-term control could
include time to flare and the use of rescue medicine [39].
Next to corticosteroid use, both these study outcomes
were included in this study as secondary parameters.
In conclusion, this study will evaluate the effects of 3-
month targeted anti-staphylococcal therapy with Staphe-
fekt in moderate to severe AD. The lack of resistance in-
duction allows long-term treatment with this anti-
staphylococcal agent. This study will provide the first data
on the use of anti-staphylococcal therapy with Staphefekt
in AD and may provide new insights into the role of S.
aureus in the pathophysiology of AD.
Trial status
The first patient was included in the study in July 2016.
Patient recruitment is currently ongoing and the recruit-
ment is expected to be completed by August 2017.
Endnotes
1“DermHome” is a secured digital treatment and re-
search platform, developed in collaboration with Patient
1 BV, Almere [33]. The platform provides a user-friendly
individual account that allows patients to report their
pruritus score and triamcinolone use daily. Thereby the
platform provides digital information about the study,
including the use of the study medication, and an option
to contact the researcher and to upload photos in case
of questions. After every visit the researcher can make
notes in the digital file about findings, agreements and
future appointments.
Additional file
Additional file 1: SPIRIT 2013 checklist: recommended items to address
in a clinical trial protocol and related documents. (DOC 121 kb)
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